Skip to main content

Home/ OARS funding Aging/ Group items tagged neuro

Rss Feed Group items tagged

MiamiOH OARS

Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent C... - 0 views

  •  
    The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.
MiamiOH OARS

NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed) - 0 views

  •  
    The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This Funding Opportunity Announcement does not accept applications proposing clinical trial(s).
MiamiOH OARS

RFA-AG-20-031: Research Education: Short Courses on Alzheimer's Disease and Related Dem... - 0 views

  •  
    The goal of this FOA is to support short courses geared to behavioral and social scientists who have existing expertise in aging research and can make research contributions in Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) with additional knowledge about the disease and related research resources. Fields of behavioral and social science research relevant for this FOA are health economics, labor economics, health services research, healthcare policy, public policy, demography, sociology, social epidemiology, psychology, and social neuroscience. Priority areas of focus include, but are not limited to, the following: dementia care; dementia caregiver research; cognitive and dementia epidemiology; behavioral and social pathways of AD/ADRD; role of social, contextual, environmental, and institutional factors in AD/ADRD; early psychological changes preceding AD/ADRD onset; prevention of AD/ADRD; disparities in AD/ADRD or dementia-related outcomes; and research resources and methods for studying the determinants and impact of AD/ADRD.
MiamiOH OARS

RFA-AG-20-006: Interpersonal Processes in Alzheimer's Disease and Related Dementias Cli... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) invites applications focused on interpersonal processes in the context of triadic interactions in clinical contexts involving caregivers, individuals with Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD), and health care practitioners and the impact of those processes on patient outcomes. The goal of this initiative is to support research that can lead to the development of interventions for optimizing communication among patients, caregivers, and healthcare practitioners and for preserving strong and supportive caregiving relationships throughout disease progression along the continuum of care for people with AD/ADRD. To these ends, basic research and translational research is solicited in two high-priority areas: (1) effective communications and relationships among patients, healthcare practitioners, and caregivers; and (2) associations between close relationship processes and health in caregiving relationships.
MiamiOH OARS

RFA-AG-20-040: Oscillatory Patterns of Gene Expression in Aging and Alzheimers Disease ... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) invites applications that seek to enhance existing transcriptome and proteome data sets by revealing oscillatory patterns of gene expression in aging and in Alzheimer's disease (AD), by uncovering their molecular significance, and by identifying rhythmic gene and/or protein profiles associated with the risk for AD. Outcomes of this research may suggest novel opportunities for translational research to allow development of individualized, optimized treatment based on circadian phase and amplitude.
MiamiOH OARS

PA-19-270: PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Tr... - 0 views

  •  
    This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R&D mission(s) of the NIH awarding components identified in this FOA are encouraged to submit STTR grant applications in response to identified topics (see PHS 2019-2 SBIR/STTR Program Descriptions and Research Topics for NIH.
MiamiOH OARS

PAR-19-269: Cognitive Systems Analysis of Alzheimer's Disease Genetic and Phenotypic Da... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) invites applications that propose Artificial Intelligence (AI), Machine Learning (ML), and/or Deep Learning (DL) approaches, collectively referred to here as "cognitive systems," that lead to the identification of gene mutations/variants that cause or contribute to the risk of or protection against the development of Alzheimer's disease (AD) and Alzheimer's disease related dementias (ADRD) via analysis of a variety of genetic, genomic, and biomarker data that are currently available to the research community.
MiamiOH OARS

RFA-AG-19-009: NIA AD/ADRD Health Care Systems Research Collaboratory (U54 - Clinical T... - 0 views

  •  
    The purpose of this FOA is to solicit applications for the AD/ADRD Health Care Systems Research Collaboratory ("Collaboratory", henceforth) to improve care for persons with dementia (PWD) and their caregivers through health systems. Health and long-term systems for this FOA are defined broadly and include organizations providing care across settings to include primary and specialty outpatient care, acute inpatient care, skilled nursing and other rehabilitation facilities, residential long-term care, and home and community-based services. Organizations may be traditional health care systems (e.g., health maintenance organizations, or HMOs), health insurance companies, managed care plans, home health care providers, memory clinics, nursing homes, assisted living facilities, outpatient clinics, federally-designated health centers, hospitals, and other providers of acute and long-term care.
MiamiOH OARS

DoD Peer Reviewed Alzheimer's Quality of Life Research Award - 0 views

  •  
    FY18 PRARP QUAL Overarching Challenges: This FY18 PRARP QUAL funding opportunity requires applications to address one or more of the following FY18 PRARP QUAL Overarching Challenges: Paucity of Clinical Studies: The paucity of clinical studies to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities. This includes research into risk factors that may predispose individuals to AD/ADRD subsequent to TBI. Quality of Life: The need for technologies, assessments, interventions, or devices to benefit individuals living with the common symptoms or deficits of TBI and AD/ADRD. Caregiver Support: The need for technologies, assessments, interventions, or devices with the goal of enhancing the lives of caregivers for individuals living with the common symptoms or deficits of TBI and AD/ADRD. Epidemiology: The paucity of epidemiological research to examine the interrelationship between TBI and subsequent AD/ADRD for the military, Veteran, and civilian communities. This includes research into risk factors that may predispose individuals to AD/ADRD subsequent to TBI. FY18 PRARP QUAL Focus Areas: In addition to addressing one or more of the specified FY18 PRARP QUAL Overarching Challenges, applications should address at least one of the following FY18 PRARP QUAL Focus Areas in support of the FY18 PRARP QUAL Overarching Challenges. An application that proposes research outside of the FY18 PRARP QUAL Focus Areas is acceptable, as long as the applicant provides a strong rationale.
MiamiOH OARS

Roybal Centers for Translational Research on Dementia Care Provider Support (P30 - Clin... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) solicits Edward R. Roybal Centers for translational intervention development research for Alzheimers Disease and Alzheimers Disease related dementias care provider support. The purpose of the Roybal Centers is to develop behavioral interventions that improve the health, well-being and/or capacity of individuals and/or systems that provide care to persons with AD-ADRD. Roybal Centers will conduct Stage 0 through IV pilot studies in accordance with the multidirectional, translational NIH Stage Model, to produce potent and implementable principle-driven behavioral interventions.
MiamiOH OARS

Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) - 0 views

  •  
    The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic therapeutic agents that prevent Alzheimer's disease (AD), slow its progression or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, mechanisms of drug action, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies, or discovery activities such as high throughput screening and hit optimization.
MiamiOH OARS

2018 Part the Cloud: Translational Research Funding for Alzheimer's Disease - 0 views

  •  
    Applications will be accepted from academic investigators and small companies with lead candidate therapeutic agents that require early stage testing prior to Proof of Concept (POC) Phase 2 or 3 efficacy studies, or with lead therapeutic agents that have already established human safety data and require a small-scale pilot Proof of Mechanism (POM) study in humans to begin proving the scientific concept in humans. This award will support Phase 1 studies or pilot small- scale Phase 2a studies for repurposed drugs in normal individuals or individuals with preclinical or symptomatic Alzheimer's disease (i.e. early human studies to set the stage for efficacy studies), including single and multiple dose studies to establish safety, brain penetration and/or target engagement and POM in preparation for larger proof of concept trials. In addition, proposals may be considered that are POC to validate biological marker(s) of disease progression in a clinical trial environment. Any proposal must have a clear focus on Alzheimer's disease and related disorder and be translational in nature. All proposals should clearly and explicitly outline the measure to be investigated, the methods for study, and outcomes. Researchers from underrepresented groups are encouraged to apply.
MiamiOH OARS

Alzheimer's Disease Programs to States and Communities - 0 views

  •  
    Cooperative agreements under this funding opportunity announcement (FOA), Alzheimer's Disease Program Initiative (ADPI), are dedicated to the development and expansion of dementia-capable home and community-based service (HCBS) systems in States and Communities. There are two application options contained in this FOA, one for States (Option A) and the other for Communities (Option B). No entity would be eligible to apply for both State and Community options. The systems resulting from program activities under both program options will provide quality, person-centered services that help individuals remain independent and safe in their communities.
MiamiOH OARS

PAR-18-546: Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery an... - 0 views

  •  
    The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.
MiamiOH OARS

PAR-18-541: Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery an... - 0 views

  •  
    The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.
MiamiOH OARS

PAR-18-519: Sensory and motor system changes as predictors of preclinical Alzheimers di... - 0 views

  •  
    The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that propose either basic, clinical, or a combination of basic and clinical studies to investigate how functional changes in the sensory and/or motor systems impact the development and progression of Alzheimer's disease. Studies may include older adults and/or animal models and may employ a variety of approaches, including cellular, molecular, imaging, physiological and genetic, to address this need. For clinical studies, leveraging of existing longitudinal cohorts already collecting sensory and motor assessments is highly encouraged.
MiamiOH OARS

PAR-18-514: Testing Lifespan-Healthspan-Extension Interventions in the Models of Alzhei... - 0 views

  •  
    This funding opportunity (FOA) encourages small business technology transfer STTR research and development of commercial pharmaceutical interventions to extend lifespan and/or healthspan, to prevent, treat, and/or slow the progression of symptoms associated with Alzheimer's disease (AD) or Alzheimer's disease related dementia (ADRD) in human cells and/or tissue, in-vitro models, and/or non-human animals. Also listed under R43/44
MiamiOH OARS

RFA-AG-18-025: Consequences of amyloid protein polymorphisms in Alzheimer's disease (R0... - 0 views

  •  
    This Funding Opportunity Announcement (FOA) invites innovative research focused on understanding the consequences of amyloid protein polymorphism in regulation and initiation of early pathogenesis in Alzheimer's disease (AD). Specifically, this FOA encourages collaborative approaches designed to identify and characterize the regulation of biochemical and cellular pathways that are responsible for the differential accumulation of various protein conformers in AD clinical subtypes.
MiamiOH OARS

RFA-AG-18-027: Exosomes: From Biogenesis and Secretion to the Early Pathogenesis of Alz... - 0 views

  •  
    Alzheimer's disease (AD) is a progressive, degenerative disorder of the brain and is the most common form of dementia of the elderly. AD is the sixth leading cause of death in the United States. Prominent behavioral manifestations of AD include memory impairments and decline in other cognitive domains. Currently, at least five million Americans at age 65 and older suffer from AD, and it is projected that the number of new cases of AD will double by 2025. AD is clearly becoming a national health crisis affecting Americans across all regions of the country, and the total annual payments of health care for people with AD are projected to be more than $1 trillion in 2050. In response to this looming public health crisis, the National Alzheimer's Project Act (NAPA) was signed into law in 2011. The primary research goal of the NAPA is to prevent the onset of and develop effective treatments for AD by 2025.  As part of the strategic planning process to implement NAPA, NIH AD Research Summits were held in 2012 and 2015 and identified research priorities and strategies needed to accelerate basic research and the development of effective therapies. A FY2017 Alzheimer's disease bypass budget with milestones was published in 2015 to establish research and funding priorities in response to the NAPA and the AD Research Summits (https://www.nia.nih.gov/alzheimers/bypass-budget-FY 2017). This funding opportunity announcement was developed in response to the recommendations of the AD Research Summits to support interdisciplinary research to understand the heterogeneity and multifactorial etiology of AD.
MiamiOH OARS

Common Mechanisms and Interactions Among Neurodegenerative Diseases (R01) - 0 views

  •  
    This FOA encourages preclinical and clinical research to study whether, and how, different neurodegenerative disease processes interact with one another to initiate and/or hasten progression of neuropathology and dementia.
1 - 20 of 30 Next ›
Showing 20 items per page